7 Development of resveratrol-conjugated gold nanoparticles: interrelationship of increased resveratrol corona on anti-tumor efficacy against breast, pancreatic and prostate cancers.

8 Evaluating the Impact of Post-Treatment Self-Management Guidelines for Prostate Cancer Survivors.

9 Correction: Prostate cancer in world trade center responders demonstrates evidence of an inflammatory cascade (Molecular Cancer Research (2019) 17 (1605–1612) DOI: 10.1158/1541-7786.MCR-19-0115.Epub)

10 A Qualitative Study to Determine Barriers for Prostate Cancer Screening in Rural African-American Men.

11 "Real-world" evaluation of F-Choline PET/CT practices in prostate cancer patients and impact on changes in therapeutic strategy.

12 Prediction of significant prostate cancer in biopsy-naïve men: Validation of a novel risk model combining MRI and clinical parameters and comparison to an ERSPC risk calculator and PI-RADS.

13 Erratum: Computer simulations suggest that prostate enlargement due to benign prostatic hyperplasia mechanically impedes prostate cancer growth (Proceedings of the National Academy of Sciences of the United States of America (2019) 116 (1152–1161) DOI: 10.1073/pnas.1815735116)

14 Comparison of multivariate adaptive regression splines and logistic regression in detecting SNP-SNP interactions and their application in prostate cancer.

15 The role of salvage brachytherapy for local relapse after external beam radiotherapy for prostate cancer.

16 A History of Past Prostate Cancer Still Carries Risk After Total Knee Arthroplasty.

17 Persistent Homology for the Quantitative Evaluation of Architectural Features in Prostate Cancer Histology

18 Competing Endogenous RNA and Coexpression Network Analysis for Identification of Potential Biomarkers and Therapeutics in association with Metastasis Risk and Progression of Prostate Cancer.

19 Are superior cervical sympathetic ganglia avid on whole body 68Ga-PSMA-11 PET/magnetic resonance?: a comprehensive morphologic and molecular assessment in patients with prostate cancer.

20 Challenges and Prospects of Chimeric Antigen Receptor T-cell Therapy for Metastatic Prostate Cancer.

21 Self-assembled albumin nanoparticles for combination therapy in prostate cancer

22 The incidence proportion of erectile dysfunction in patients treated with cryotherapy for prostate cancer: a meta-analysis

23 Effect of Vitamin D Supplementation in Prostate Cancer: A Systematic Review of Randomized Control Trials.

24 Metal- and redox homeostasis in prostate cancer with vitamin D supplementation.

25 Vitamin D in prostate cancer.

26 Dose Escalation of Vitamin D Yields Similar Cryosurgical Outcome to Single Dose Exposure in a Prostate Cancer Model.

27 1,25(OH)D disrupts glucose metabolism in prostate cancer cells leading to a truncation of the TCA cycle and inhibition of TXNIP expression.

28 Phase IIa, randomized placebo-controlled trial of single high dose cholecalciferol (vitamin D) and daily Genistein (G-2535) versus double placebo in men with early stage prostate cancer undergoing prostatectomy.

29 Phase 2 trial of weekly intravenous 1,25 dihydroxy cholecalciferol (calcitriol) in combination with dexamethasone for castration-resistant prostate cancer

30 Cholecalciferol (Vitamin D3) and the retinoid N-(4-hydroxyphenyl)retinamide (4-HPR) are synergistic for chemoprevention of prostate cancer

31 Cholecalciferol (vitamin D<inf>3</inf>) inhibits growth and invasion by up-regulating nuclear receptors and 25-hydroxylase (CYP27A1) in human prostate cancer cells

32 Chemoprevention of prostate cancer by cholecalciferol (vitamin D <inf>3</inf>): 25-Hydroxylase (CYP27A1) in human prostate epithelial cells

33 Designing a randomized phase I/II prostate cancer chemoprevention trial using 1α-hydroxy-24-ethyl-cholecalciferol, an analogue of vitamin D <inf>3</inf>

34 Protective Innate Immune Variants in Racial/Ethnic Disparities of Breast and Prostate Cancer.

35 Management of patients with metastatic prostate cancer (mPC) in a rural part of North Norway with a scattered population: does living near the department of oncology translate into a different pattern of care and survival?

36 Automating the Capture of Structured Pathology Data for Prostate Cancer Clinical Care and Research.

37 Machine learning methods can more efficiently predict prostate cancer compared with prostate-specific antigen density and prostate-specific antigen velocity.

38 Photodynamic therapy for prostate cancer: a systematic review and meta-analysis.

39 Irreversible Electroporation for the Ablation of Prostate Cancer.

40 Therapeutic substitutions in the midst of new technology diffusion: The case of treatment for localized prostate cancer.

41 Targeting prostate cancer cell proliferation, stemness and metastatic potential using derived phytochemicals.

42 Illness uncertainty, partner support, and quality of life: A dyadic longitudinal investigation of couples facing prostate cancer.

43 MicroRNA biogenesis, gene silencing mechanisms and role in breast, ovarian and prostate cancer.

44 Prediction of prostate cancer aggressiveness with a combination of radiomics and machine learning-based analysis of dynamic contrast-enhanced MRI.

45 Repeatability of tumor blood flow quantification with <sup>82</sup>Rubidium PET/CT in prostate cancer — a test-retest study

46 Biological and molecular modifications induced by cadmium and arsenic during breast and prostate cancer development.

47 Quality of YouTube patient information on prostate cancer screening

48 Overexpression of certain transient receptor potential and Orai channels in prostate cancer is associated with decreased risk of systemic recurrence after radical prostatectomy.

49 Preparing Nanoarchaeosome Containing Triptorelin Acetate and Evaluation of Its Cellular Toxic Effect on PC3 Prostate Cancer Cell Line

50 A CTGF-RUNX2-RANKL Axis in Breast and Prostate Cancer cells Promotes Tumor Progression in Bone.

51 [The impact of the androgen receptor splice variant AR-V7 on the prognosis and treatment of advanced prostate cancer].

52 The need for cell lines from diverse ethnic backgrounds for prostate cancer research.

53 Achieving optimal delivery of follow-up care for prostate cancer survivors: improving patient outcomes

54 Global Patterns of Prostate Cancer Incidence, Aggressiveness, and Mortality in Men of African Descent

55 Association of the extent of therapy with prostate cancer in those receiving testosterone therapy in a US commercial insurance claims database.

56 The Effect of Salvage Radiotherapy and its Timing on the Health-related Quality of Life of Prostate Cancer Patients.

57 Biobehavioral effects of Tai Chi Qigong in men with prostate cancer: Study design of a three-arm randomized clinical trial

58 Synthesis, Anticancer Activity on Prostate Cancer Cell Lines and Molecular Modeling Studies of Flurbiprofen-Thioether Derivatives as Potential Target of MetAP (type II).

59 The association between ethnic background and prostate cancer.

60 Vortioxetine reverses medial prefrontal cortex-mediated cognitive deficits in male rats induced by castration as a model of androgen deprivation therapy for prostate cancer.

61 Psychological distress among prostate cancer survivors in South Korea: A nationwide population-based, longitudinal study.

62 Enhanced Patient Activation in Cancer Care Transitions: Protocol for a Randomized Controlled Trial of a Tailored Electronic Health Intervention for Men With Prostate Cancer.

63 Problems sleeping with prostate cancer: exploring possible risk factors for sleep disturbance in a population-based sample of survivors.

64 Co-Occurring Symptoms Contribute to Persistent Fatigue in Prostate Cancer.

65 Measuring a new facet of post traumatic growth: Development of a scale of physical post traumatic growth in men with prostate cancer.

66 Factors associated with the use of complementary and alternative medicines for prostate cancer by long-term survivors.

67 Predictors of long-term distress in female partners of men diagnosed with prostate cancer.

68 Depressive Symptoms and Health-Related Quality of Life among Prostate Cancer Survivors

69 Correction to Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial (The Lancet Oncology (2019) 20(3) (408–419), (S147020451830860X), (10.1016/S1470-2045(18)30860-X))

70 Author Correction: Doxorubicin Conjugated to Immunomodulatory Anticancer Lactoferrin Displays Improved Cytotoxicity Overcoming Prostate Cancer Chemo resistance and Inhibits Tumour Development in TRAMP Mice (Scientific Reports, (2016), 6, 1, (32062), 10.1038/srep32062)

71 Evaluation of Small Molecule Drug Uptake in Patient-Derived Prostate Cancer Explants by Mass Spectrometry.

72 Nutraceutical treatment and prevention of benign prostatic hyperplasia and prostate cancer.

73 Late toxicities of prostate cancer radiotherapy with and without hydrogel SpaceAOR insertion.

74 Transitioning to whole-body SPECT/CT in prostate cancer staging: a new concept for a better imaging workflow.

75 Author Correction: Germline variation at 8q24 and prostate cancer risk in men of European ancestry.

76 Author Correction: Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci.

77 Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants

78 Germline variation at 8q24 and prostate cancer risk in men of European ancestry

79 (11)C-Choline PET/CT for restaging prostate cancer. Results from 4,426 scans in a single-centre patient series.

80 Total Medicare Costs Associated With Diagnosis and Treatment of Prostate Cancer in Elderly Men.

81 Vitamin D in prostate cancer

82 Consensus Procedures in Oncological Imaging: The Case of Prostate Cancer.

83 A step towards equitable clinical trial recruitment: a protocol for the development and preliminary testing of an online prostate cancer health information and clinical trial matching tool.

84 Forecasting annual incidence and mortality rate for prostate cancer in Australia until 2022 using autoregressive integrated moving average (ARIMA) models

85 Reply to Xueliang Zhou and Xinwei Han's Letter to the Editor re: Thomas Van den Broeck, Roderick C.N. van den Bergh, Nicolas Arfi, et al. Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review. Eur Urol 2019;75:967–87

86 Optimal threshold of the prostate health index in predicting aggressive prostate cancer using predefined cost-benefit ratios and prevalence.

87 Asporin is a stromally expressed marker associated with prostate cancer progression

88 Germline variants in asporin vary by race, modulate the tumor microenvironment, and are differentially associated with metastatic prostate cancer

89 Cardiovascular Risk in Men with Prostate Cancer: Insights from the RADICAL PC Study.

90 Histogram analysis from stretched exponential model on diffusion-weighted imaging: evaluation of clinically significant prostate cancer.

91 A case report of monitoring PSA level changes in two prostate cancer patients treated with Mountain Ginseng Pharmacopuncture and Sweet Bee Venom along with western anticancer therapy

92 Health Care Integration and Quality among Men with Prostate Cancer.

93 Sleep disorder due to radiotherapy after prostate cancer - Case report and expert opinion

94 Synthesis and biological evaluation of some novel 1,2,3-triazole hybrids of myrrhanone B isolated from Commiphora mukul gum resin: Identification of potent antiproliferative leads active against prostate cancer cells (PC-3).

95 Synthesis and biological evaluation of some novel 1,2,3-triazole hybrids of myrrhanone B isolated from Commiphora mukul gum resin: Identification of potent antiproliferative leads active against prostate cancer cells (PC-3)

96 Diagnostic Impacts of Clinical Laboratory Based p2PSA Indexes on any Grade, Gleason Grade Group 2 or Greater, or 3 or Greater Prostate Cancer and Prostate Specific Antigen below 10 ng/ml

97 Predictive factors of prostate cancer diagnosis with PSA 4.0–10.0 ng/ml in a multi-ethnic Asian population, Malaysia

98 Detection of Dominant Intra-prostatic Lesions in Patients With Prostate Cancer Using an Artificial Neural Network and MR Multi-modal Radiomics Analysis.

99 Replay by authors: Serum testosterone level is a useful biomarker for determining the optimal treatment for castration-resistant prostate cancer.

100 Re: Nicolas Mottet, Joaquim Bellmunt, Erik Briers, et al. EAU-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. European Association of Urology; 2017. http://uroweb.org/guideline/prostate-cancer: How to Assess the Efficacy of Medical Castration.

101 Hybrid Unified Deep Learning Network for Highly Precise Gleason Grading of Prostate Cancer.

Keyword Connections

Journals

Research Groups

Bibliographies